Skip to content
Events

Details

New avenues to better understand development and progression of cancer have been opened using liquid biopsy analyses. In research settings, these samples are providing rich insights to enable new discoveries through the combined analysis of genomic, transcriptomic, epigenomic and proteomic data.

In this sponsored industry symposium recorded at EACR 2024, Anna Babayan (Illumina) gives a short introduction into the current state of liquid biopsy as a research tool and Amin El-Heliebi (Med Uni Graz) discusses how multi-analyte liquid biopsy analysis enables translational applications such as analysis of treatment resistance in prostate cancer.

Provide your contact details to access the on demand recording.

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
14 Oct 2024
Location
Europe
Presenter
Dr. Anna Babayan, Dr Amin El-Heliebi
Topic
Cancer research
Watch Now
M-EMEA-01533
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.